Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - IOVANCE BIOTHERAPEUTICS, INC.Financial_Report.xls
EX-32.1 - EXHIBIT 32.1 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex31-2.htm
EX-10.10 - EXHIBIT 10.10 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex10-10.htm
EX-10.13 - EXHIBIT 10.13 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex10-13.htm
EX-10.24 - EXHIBIT 10.24 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex10-24.htm
EX-10.14 - EXHIBIT 10.14 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex10-14.htm
EX-10.10B - EXHIBIT 10.10(B) - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex10-10b.htm
10-K - FORM 10-K - IOVANCE BIOTHERAPEUTICS, INC.v307730_10k.htm
EX-4.3 - EXHIBIT 4.3 - IOVANCE BIOTHERAPEUTICS, INC.v307730_ex4-3.htm

Exhibit 32.2

 

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

 

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Genesis Biopharma, Inc. (the “Company”) hereby certifies that, to his knowledge:

 

(iii)             The Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2012 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

(iv)             The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:  March 29, 2012 By:  /s/ MICHAEL HANDELMAN
    Name: Michael Handelman
    Title: Chief Financial Officer and Treasurer